Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
Open accessThe DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
High inter-patient variability and high spatial heterogeneity are features of colorectal cancer (CRC). This may influence the molecular characterization of tumor tissue, now mandatory for patients with metastatic CRC who are candidates for treatment with an anti-EGFR mAb, as false-negative results can occur, leading to non optimal therapy. Moreover, temporal molecular heterogeneity during treatment is known to influence the response to therapy and prognosis. We present a literature overview of advances made in characterizing molecular heterogeneity in CRC, underlining that the analysis of liquid biopsy could represent an efficient non-invasive tool to overcome the problem. We believe that understanding CRC heterogeneity is fundamental for a more accurate diagnosis, for selecting the best targets to ensure prolonged antitumor response, and for monitoring minimal residual disease and the onset of resistance to therapy, all essential components of successful personalized treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Heterogeneity, or more specifically, the diverse cell populations within the diseased tissue, is the leading cause of treatment failure for many complex diseases, such as cancers1, Alzheimer’s disease2, stroke3, and coronavirus disease 2019 (COVID-19)4, etc., as well as a major obstacle to successful precision medicine5–7.”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“The majority of sporadic CRCs (almost 85%) arise from adenomas according to the model proposed by Fearon and Vogelstein in 1990 [16].”
BackgroundSiegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · cited 2×
“Finally, distinct mutations can also co-exist within the cells of a single metastatic lesion [7].”
BackgroundGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“to classify CRCs into four subtypes [12,22,29].”
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 2×
“In Europe the overall survival (OS) rate for mCRC is estimated at 12%, with a median OS of 30 months [3].”
BackgroundClonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840 · cited 1×
“The lack of accurate standard methods to assess ITH is currently limiting our ability to explore its clinical implications [39].”
BackgroundIntra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000 · cited 1×
“In fact, a higher spatial and temporal variability of tumor microenvironment components, such as stromal, inflammatory, and microbial cells, may translate into a higher phenotypic heterogeneity of tumor cells [30].”
Background
Cited by
Items 101–200 of 272
Chen, J., Dai, J., Kang, Z., Yang, T., Zhao, Q., Zheng, J., Zhang, X., Zhang, J., Xu, J., Sun, G., et al. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112060 · Cited by 12
Silva, V. S. E., Abdallah, E. A., Brito, A. B. C., Braun, A. C., Tariki, M. S., de Mello, C. A. L., Calsavara, V. F., Riechelmann, R. P., & Chinen, L. T. D. (2021) · Diagnostics · doi:10.3390/diagnostics11030502 · Cited by 11
“Advances provided by liquid biopsy open new opportunities for the discovery of biomarkers to forecast more accurate prognoses, to assess drug resistance before and during therapy, and to monitor treatment response [11,25,43].”
BackgroundFatfat, Z., Hussein, M. M., Fatfat, M., & Gali‐Muhtasib, H. U. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100200 · Cited by 12
“On the other hand, CRC is characterized by high inter-patient heterogeneity and high intra-tumor heterogeneity that could be responsible for the variation in the treatment sensitivity and prognosis for CRC patients (Dey et al., 2023; Molinari et al., 2018).”
Adaptive Control of Tumor Growth
Derbal, Y. (2024) · Cancer Control: Journal of the Moffitt Cancer Cente · doi:10.1177/10732748241230869 · Cited by 9
Weng, M., Li, T., Zhao, J., Guo, M., Zhao, W., Gu, W., Sun, C., Yue, Y., Zhong, Z., Nan, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.950782 · Cited by 10
“At the same time, due to the high molecular heterogeneity of CRC, most existing biomarkers lack strong predictive accuracy (5).”
BackgroundAdvances in Mapping Tumor Progression from Precancer Atlases
Chen, Z., & Lau, K. S. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-22-0473 · Cited by 10
Distinctive chromosomal, mutational and transcriptional profiling in colon versus rectal cancers
Angelis, M. T. D., Rizzuto, A., Amaddeo, A., Sagnelli, C., Vono, N., Reda, M., Lise, V., Parrillo, L., Marco, C. D., Malanga, D., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06908-2 · Cited by 11
“In fact, despite considerable progress in therapeutic strategies, almost a third of CRC patients recur [2–4].”
Therapeutic Cancer Vaccines in Colorectal Cancer: Platforms, Mechanisms, and Combinations
Gallio, C., Esposito, L., & Passardi, A. (2025) · Cancers · doi:10.3390/cancers17152582 · Cited by 10
“CRC exhibits extensive inter-and intra-patient variability at the genetic, epigenetic, and antigenic levels, which limits the efficacy of “one-size-fits-all” vaccines and highlights the need for personalized or precision vaccine strategies [53].”
Self-citationSynergistic cytotoxicity of perifosine and ABT ‐737 to colon cancer cells
Adamová, B., Říhová, K., Pokludová, J., Beneš, P., Šmarda, J., & Navrátilová, J. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17636 · Cited by 9
A novel f-divergence based generative adversarial imputation method for scRNA-seq data analysis
Si, T., Hopkins, Z., Yanev, J., Hou, J., & Gong, H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292792 · Cited by 12
“Clinical studies have found that many drugs are not effective to some patients due to the cellular diversity or heterogeneous effects across individuals [10].”
Yuan, T., Wankhede, D., Edelmann, D., Kather, J. N., Tagscherer, K. E., Roth, W., Bewerunge‐Hudler, M., Brobeil, A., Kloor, M., Bläker, H., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105223 · Cited by 9
Shahabi, F., Mehri, A., Abdollahi, A., Hoshyar, S. H. H., Ghahramani, A., Noei, M. G., Orafaie, A., & Ansari, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-67852-7 · Cited by 10
“In advanced rectal cancer, post-recurrence survival (PRS) is typically related to the characteristics of the tumor and patient at the time of diagnosis, including the tumor’s site, probability of surgical resection, performance status, and disease burden 11,12 .”
BackgroundHybrid near-infrared-activated luminescent gold nanoparticle platform for efficient cancer therapy
Yan, F., Li, R., Liu, J., Yang, L., Liu, H., Zhu, S., Zhang, Y., Wang, L., Huang, L., Wang, Y., et al. (2025) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-024-01141-9 · Cited by 10
“As the third most common malignancy and the second most deadly cancer, colorectal cancer (CRC) is a highly heterogeneous and malignant tumor with a high risk of recurrence Feihong Yan, Ruiyuan Li, and Jiaxin Liu contributed equally to this work. and metastasis [1–11].”
Almuzzaini, B., Alghamdi, J., Alomani, A. A., Alghamdi, S. A. A., Alsharm, A. A., Alshieban, S., Sayed, A., Alhejaily, A., Aljaser, F., Abudawood, M., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060535 · Cited by 9
“Though our study is limited with smaller number of patient samples, it does exhibit the heterogeneous nature of CRC [36].”
BackgroundOverview of serum and tissue markers in colorectal cancer: a primer for radiologists
Bonde, A. A., Smith, D. A., Kikano, E. G., Yoest, J. M., Tirumani, S. H., & Ramaiya, N. H. (2021) · Abdominal Radiology · doi:10.1007/s00261-021-03243-0 · Cited by 9
Impact of automated methods for quantitative evaluation of immunostaining: Towards digital pathology
Elie, N., Giffard, F., Blanc‐Fournier, C., Morice, P., Brachet, P.-E., Dutoit, S., Plancoulaine, B., & Poulain, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931035 · Cited by 10
“Frontiers in Oncology 14 Another potential source of discordance is that, in the classification of immunostainings as low, medium, or high, there is no appreciation of an eventual intra-tumor heterogeneity, yet this could be decisive in the therapeutic management of patients (26, 27).”
BackgroundSuwatthanarak, T., Thanormjit, K., Suwatthanarak, T., Acharayothin, O., Methasate, A., Chinswangwatanakul, V., & Tanjak, P. (2024) · Life · doi:10.3390/life14010126 · Cited by 11
“This observation also aligns with previous studies, which demonstrated the heterogeneity of CC tumors, and supports the notion that different tumor compartments contribute to tumor growth, invasion, and metastasis [27].”
ResultAird, J. J., Steel, M. J., Chow, C., Ho, J., Wolber, R. A., Gilks, C. B., Hoang, L. N., & Schaeffer, D. F. (2019) · Histopathology · doi:10.1111/his.14026 · Cited by 9
“Intratumoral heterogeneity is also thought to play a role in resistance to systemic therapy, with resistant clones surviving and causing metastases or local recurrences.(20) Intratumoral heterogeneity of MMR status has been reported in both CRC and endometrial carcinoma,(21,22) as has intertumoral heterogeneity, where…”
BackgroundZhou, X., Dai, J., Lu, Y., Zhao, Q., Liu, Y., Wang, C., Zhao, Z., Wang, C., Gao, Z., Yu, Y., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13292-5 · Cited by 9
Xu, Y., Guo, J., Yang, N., Zhu, C., Zheng, T., Zhao, W., Liu, J., & Song, J. H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1353446 · Cited by 11
“Nevertheless, it remains inadequate for accurately forecasting the fate of certain rectal patients, speci fi cally those in clinical stages II and III (7, 8).”
High expression of RUNX1 in colorectal cancer subtype accelerates malignancy by inhibiting HMGCR
Chang, Z., Liu, B. Y., He, H., Li, X., & Shi, H. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107293 · Cited by 8
Oxidative Phosphorylation as a Predictive Biomarker of Oxaliplatin Response in Colorectal Cancer
Martínez-Bernabé, T., Pons, D. G., Oliver, J., & Sastre‐Serra, J. (2024) · Biomolecules · doi:10.3390/biom14111359 · Cited by 10
“Drug administration could affect cellular diversity within the tumor differently, in which cancer stem cells (CSCs) are present [36].”
Salehitabar, E., Mahdevar, M., Motlagh, A. V., Forootan, F. S., Feizbakhshan, S., Zohrabi, D., & Peymani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02694-9 · Cited by 8
Bonilla, C., Montenegro, P., O’Connor, J. M., Hernando, O., Aranda, E., Pinto-Llerena, J., Llontop, A., Escobar, J. G., Romero, M. D. C. D., Bautista-Hernández, Y., et al. (2023) · Cancers · doi:10.3390/cancers15174373 · Cited by 8
“• Since tumor re-biopsy is an invasive procedure (which may not be feasible), the only opportunity to investigate and monitor these alterations during treatment is liquid biopsy [109].”
BackgroundBioinformatics for The Prognostic Value and Function of Cubilin (CUBN) in Colorectal Cancer
Wu, Y., & Xu, Y. (2020) · Medical Science Monitor · doi:10.12659/msm.922447 · Cited by 9
“The heterogeneity of CRC makes it difficult to determine which patients need further therapy beyond surgical resection and which patients have a poor prognosis [18].”
BackgroundYaung, S. J., Ju, C., Gattam, S., Nicholas, A., Sommer, N., Bendell, J. C., Hurwitz, H. I., Lee, J. J., Casey, F., Price, R., et al. (2022) · Cancers · doi:10.3390/cancers14092240 · Cited by 6
“Colorectal cancer (CRC) is characterized by high molecular heterogeneity [1,2].”
BackgroundLong, F., Tian, L., Chai, Z., Li, J., Tang, Y., & Liu, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.881788 · Cited by 8
“Previous studies have shown that high inter-patient and intra-tumor heterogeneity promotes CRC metastasis and patient deterioration (3).”
BackgroundSuwatthanarak, T., Tanjak, P., Suwatthanarak, T., Acharayothin, O., Thanormjit, K., Chaiboonchoe, A., Tawantanakorn, T., Phalanusitthepha, C., Trakarnsanga, A., Methasate, A., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11595-7 · Cited by 6
Targeted Nanoparticles: the Smart Way for the Treatment of Colorectal Cancer
Abdellatif, A. A. H., Alshubrumi, A. S., & Younis, M. A. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02734-9 · Cited by 8
“Further research is needed for a better understanding of the heterogeneity of CRC and how it may impact the effectiveness of targeted nanoparticle-based treatments [147].”
Ke, T., Chang, S., Yeh, C., Lin, S., & Yeh, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-90025-z · Cited by 6
Precision Medicine for the Management of Therapy Refractory Colorectal Cancer
Taghizadeh, H., Mader, R. M., Müllauer, L., Erhart, F., Kautzky‐Willer, A., & Prager, G. W. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040272 · Cited by 7
Vuijk, F. A., van de Water, C., van Vliet, S., van der Valk, M. J. M., Simmer, F., van de Velde, C. J. �., Vahrmeijer, A. L., Nagtegaal, I. D., & Hilling, D. E. (2021) · Cancers · doi:10.3390/cancers13092271 · Cited by 7
Villanueva, J., Kwong, L. N., Han, T., Martinez, S. A., Shanahan, M. T., Kanke, M., Dow, L. E., Danko, C. G., & Sethupathy, P. (2022) · BMC Genomics · doi:10.1186/s12864-022-09018-1 · Cited by 7
Simu, P., Jung, I., Banias, L., Kovács, Z., Fülöp, Z. Z., Bara, T., Simu, I. P., & Gurzu, S. (2021) · Diagnostics · doi:10.3390/diagnostics11020314 · Cited by 6
“Exogenous factors such as diet, lifestyle, environment, and microbiome influence immune system cells and aberrant differentiation, and they can also contribute to the heterogeneity of the neoplastic process [10].”
BackgroundTong, Y., Peng, M., Li, J., & Niu, Y. (2022) · Disease Markers · doi:10.1155/2022/4235305 · Cited by 7
“…chemotherapy serves as the main therapeutic strategy for colon cancer [2], however, owing to remarkable disease heterogeneity, the survival outcomes remain poor, and the 5-year overall survival rate is ~ 60% [3, 4], which urges for an investigation into novel therapeutic targets for colon cancer.”
Incidência dos casos de dengue na Região Oeste do Mato Grosso de 2015 a 2020
CURSOS, L. C. E. &., Paulani, A. P. I. R., Borges, D. G. A., Pereira, H. I. F., Motta, A. M. D. S., da Silva, T. K. S., da Silva, T. A., Santos, C. S., Cardoso, L. P. D. S., da Fonseca, A. F., et al. (2022) · Literacia Cientifica Editora & Cursos eBooks · doi:10.53524/lit.edt.978-65-84528-12-3/28 · Cited by 1
Chen, C., Shao, Y., Fan, X., Huang, Z., Lu, T., Gao, R., Yu, Q., Li, S., Huang, Q., Yang, X. F., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01217-9 · Cited by 5
“Additionally, the invasive nature and biological heterogeneity of CRC pose challenges to its treat-ment and management 6,7 .”
Ulivi, P., Passardi, A., Marisi, G., Chiadini, E., Molinari, C., Canale, M., Pasini, L., Ferroni, F., Frassineti, G. L., Bartolini, G., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.745701 · Cited by 5
“This is true, in particular, if the mutation is heterogeneously present within the tumor (Gargalionis and Papavassiliou, 2017; Khan et al., 2018; Molinari et al., 2018).”
BackgroundSelf-citationAD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy
de Almeida, L. C., Carlos, J. A. E. G., Teixeira, P. R., Machado‐Neto, J. A., & Costa-Lotufo, L. V. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120911 · Cited by 6
Marbun, V. M. G., Lalisang, T. J. M., & Erlina, L. (2021) · Research Square · doi:10.21203/rs.3.rs-900277/v2 · Cited by 5
Notter, S., Choezom, D., Griebel, T., Ramos‐Gomes, F., Möbius, W., Oliveira, T. D., Conradi, L., Alves, F., & Feldmann, C. (2024) · Small Science · doi:10.1002/smsc.202400196 · Cited by 4
Transferrin receptor 1-targeted polymersomes therapy for colorectal cancer
Pina, A., Mastrantuono, E., da Silva, M. C. P., Barbieri, V., Muñoz-López, J., Battaglia, G., Graça, L., & Matias, D. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102263 · Cited by 4
“CRC is highly heterogeneous within individual tumors and across patients, with factors such as tumor location and interactions with immune cells contributing to its complex pathogenesis [2,3].”
TCox: Correlation-Based Regularization Applied to Colorectal Cancer Survival Data
Peixoto, C., Lopes, M. B., Martins, M., Costa, L., & Vinga, S. (2020) · Biomedicines · doi:10.3390/biomedicines8110488 · Cited by 4
“This genomic instability may lead to a higher inter-patient and intra-tumor heterogeneity, being a great challenge for both diagnosis and cancer therapy [5,6].”
BackgroundSmorodin, E. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111608 · Cited by 4
Sciberras, P., Grech, L., & Grech, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10214999 · Cited by 4
“Systemic chemotherapy in the adjuvant and advanced settings has evolved considerably in the past decades from basic cytotoxic agents to combination regimens and, more recently, the introduction of biological agents targeting specific signaling pathways [9,10].”
BackgroundCallesen, L. B., Boysen, A. K., Andersen, C. S. A., Pallisgaard, N., & Spindler, K. G. (2023) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2023.07.005 · Cited by 7
Redefining colorectal cancer classification and clinical stratification through a single-cell atlasPreprint
Khaliq, A. M., Kurt, Z., Grunvald, M. W., Erdoğan, C., Turgut, S. S., Rand, T., Khare, S., Borgia, J. A., Hayden, D. M., Pappas, S. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.02.429256 · Cited by 4
Ito, K., Osakabe, M., Sugimoto, R., Yamada, S., Sato, A., Uesugi, N., Yanagawa, N., Suzuki, H., & Sugai, T. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12574-1 · Cited by 3
“Such heterogeneous changes may promote neoplastic progression and cancer metastasis.(8,9) As a result, tumor clones expressing genes responsible for cancer progression and metastatic potential are selected as driver clones.”
BackgroundAzizi, M., Mokhtari, Z., Tavana, S., Bemani, P., Heidari, Z., Ghazavi, R., & Rezaei, M. (2024) · Current Therapeutic Research · doi:10.1016/j.curtheres.2024.100760 · Cited by 3
Chen, S., Shi, X., Liu, S. Q., Pei, P., Yang, K., & Hu, L. (2024) · Journal of intelligent medicine. · doi:10.1002/jim4.16 · Cited by 3
Cotton, S., Ferreira, D., Relvas‐Santos, M., Brandão, A., Afonso, L. P., Miranda, A., Ferreira, E., Santos, B., Gonçalves, M., Lopes, P., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13733 · Cited by 6
“The challenges associated with CRC are amplified by late-stage diagnoses and the limited effi-cacy of existing therapeutics against advanced disease [2].”
CRC management: Emerging trends in early detection, diagnosis, biomarkers, treatment, and prevention
Alotaibi, A. G., Alfozan, B. A., Alotaibi, S. S., Mutairi, A. A., Humoudi, A. Y. A., Aljawini, N., Alshehri, A. H., Albahlal, H. N., & Alghamdi, S. S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156206 · Cited by 4
Genomic Landscape of Actionable Mutations in Primary and Metastatic Tissues of Colon Adenocarcinoma
Yekedüz, E., Akbulut, H., Utkan, G., & Ürün, Y. (2022) · Cureus · doi:10.7759/cureus.24175 · Cited by 4
“For instance, BRAF mutations and microsatellite instability (MSI) were more frequent in rightsided tumors [5].”
BackgroundCharacterization of Spatial Heterogeneity in Metastasized Colorectal Cancer by MALDI ImagingPreprint
Moritz, L., Stillger, M. N., Takács, F., Füllgraf, H., Werner, M., Fichtner‐Feigl, S., Jud, A., Schilling, O., & Föll, M. C. (2023) · Preprints.org · doi:10.20944/preprints202302.0363.v1 · Cited by 3
Altaf, A., Kawashima, J., Khalil, M., Stecko, H., Rashid, Z., Kalady, M. F., & Pawlik, T. M. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.109718 · Cited by 3
Zhao, W., Qiu, Y., Bai, N., He, C., Yin, J. C., Xu, Q., Jian, K., Jia, B., Jiang, L., & Liang, F. (2026) · Cancer Medicine · doi:10.1002/cam4.71534 · Cited by 2
“When comparing the molecular landscapes of LCC and RCC, distinctive divergence is evident, further reinforcing and expanding upon previously established findings [15, 42–44].”
Luo, D., Yang, Y., Shan, Z., Liu, Q., Cai, S., Li, Q., & Li, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.618820 · Cited by 2
“CRC is characterized by heterogeneity with distinctive survival outcomes (5).”
BackgroundHamed, R., Marks, S., McElligott, H., Kalachand, R. D., Ibrahim, H., Atyani, S., Korpanty, G., & Osman, N. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2472 · Cited by 2
Clinical Significance of Genetic Variants in Colon Cancer
Nakashidze, I., Petrović, N., Kedelidze, N., & Dariya, B. (2022) · Springer eBooks · doi:10.1007/978-3-030-72702-4_4 · Cited by 4
High expression of ZEB1 is associated with EMAST & metastasis in colorectal cancer patients
Mohammadpour, S., Esfahani, A. T., Khorasaniasl, S., Karimpour, R., Bakhshian, F., Moradi, A., & Mojarad, E. N. (2022) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_1062_20 · Cited by 2
Wątor, G., Seweryn, M. T., Kapusta, P., Świrta, J. S., Walega, P. J., Barczyński, M., & Wołkow, P. P. (2023) · Clinical Genetics · doi:10.1111/cge.14388 · Cited by 2
“are still no guidelines for proper sampling in order to capture representative features of the entire tumor, apart from a recommendation that at least two biopsies should be acquired from different parts of the tumor to avoid insufficient sampling.(5) Recent studies on ITH of clinically relevant mutations in CRC have…”
ResultNGUYEN, S. V., Shamoun, L., Landerholm, K., Wågsäter, D., & Dimberg, J. (2024) · In Vivo · doi:10.21873/invivo.13628 · Cited by 2
“Through its interpatient and intratumor heterogeneity, CRC can have a pronounced effect on both treatment and prognosis (6).”
Backgroundde Lucas, B. P., Heras, B., Tarazona, N., Ortega, M., Huerta, M., Moro, D., Roselló, S., Roda, D., Pla, V., Cervantes, A. M. R., et al. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155871 · Cited by 3
Mechanistic insights into the heterogeneous response to anti‐VEGF treatment in tumors
Ding, L., & Finley, S. D. (2021) · Computational and Systems Oncology · doi:10.1002/cso2.1013 · Cited by 3
Genomic landscape of treatment refractory metastatic colorectal cancer
Eefsen, R. L., Simonsen, K. S., Grundtvig, P., Klarskov, L. L., Chen, I. M., Høgdall, D., Jensen, B. V., Lorentzen, T., Poulsen, T. S., Theile, S., et al. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1984575 · Cited by 2
“Despite some advances in the cytotoxic and targeted therapies, metastatic CRC (mCRC) is still one of the leading causes of cancer-related death, as targeted treatment possibilities are limited and heterogeneity is a challenge [8].”
BackgroundHe, J., & Wu, W. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2022.2124537 · Cited by 2
“However, interpatient variability and high spatial heterogeneity are essential characteristics of CRC [77].”
BackgroundBádon, E. S., Mokánszki, A., Mónus, A., András, C., & Méhes, G. (2022) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2022.101891 · Cited by 2
Dimberg, J., Shamoun, L., GEIJERSTAM, K. A. F., Landerholm, K., & Wågsäter, D. (2024) · Oncology · doi:10.1159/000540887 · Cited by 3
“Molecular biomarkers may be important to detect CRC and to determine prognosis as well as to meet the demand for a more personalized treatment following increased awareness that CRC is a heterogeneous disease [4, 5].”
InfluentialSpecial Issue on Basic and Translational Research in Colorectal Cancer
Ulivi, P., Scarpi, E., & Passardi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123095 · Cited by 2
“Temporal molecular heterogeneity may also occur during treatment and can influence response and prognosis [13].”
BackgroundSelf-citationThe expression patterns of NBAT1 and CASC15 are associated with colorectal cancer
Amir-Shahkarami, M., & Peymani, M. (2020) · Gene Reports · doi:10.1016/j.genrep.2020.100876 · Cited by 1
Shaukat, A., Lichtenstein, D. R., Chung, D. C., Seidl, C., Wang, Y., Navajas, E. E., Colucci, D. R., Baxi, S. S., & Brugge, W. R. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.06.040 · Cited by 1
Egbuchiem, A. N., Okobi, O. E., Odutola, O. D., Igbenabor, C. A., Okey-Ndeche, U. N., Omotunde, O., Ayantoyinbo, T., Abonyi, O. C., Oghotuoma, O. O., Nnabude, O. H., et al. (2025) · Cureus · doi:10.7759/cureus.84530 · Cited by 1
“In contrast, left-sided tumors typically exhibit chromosomal instability (CIN) and a gene expression profile marked by activation of the epidermal growth factor receptor (EGFR) pathway [8,9,10].”
Lee, C., Park, S., Han, I., & Yoon, S. K. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02731-2 · Cited by 1
“Despite the diversi fi cation and advancements in cancer treatments leading to improved clinical outcomes for CRC patients, the prognosis remains poor due to the high heterogeneity and complexity of CRC [2, 3].”
Okotel, M., & Huang, C. (2025) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2025060830 · Cited by 1
Said, K. B., Alshammari, K. F., Ahmed, R. M. E., Zakout, Y. M.-A., Moursi, S. A., Binsaleh, N. K., ALSHAMMARY, F. M., Alotaibi, A. A., Alzugahibi, M. S., Alshammari, M. A., et al. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2580036 · Cited by 1
“Such genetic heterogeneity can manifest in a wide array of clinical presentations and diverse pathological features, often posing considerable diagnostic challenges 20 .”
Zhang, P., Tang, X., Akanyibah, F. A., Du, S., & Mao, F. (2025) · Laboratory Investigation · doi:10.1016/j.labinv.2025.104256 · Cited by 1
Joint Bayesian additive regression trees for multiple nonlinear dependency networks
Huang, L., Peterson, C. B., & Ha, M. J. (2025) · Biometrics · doi:10.1093/biomtc/ujaf158 · Cited by 2
Sun, Q., Sun, R., He, B., Meng, H., & Jin, J. (2026) · International Journal of Colorectal Disease · doi:10.1007/s00384-025-05067-6 · Cited by 1
“Approximately one-third of patients experience disease recurrence following radical surgical resection and chemotherapy, with the 5-year survival rate for metastatic CRC lingering around 14% [4–6].”
InfluentialRadloff, H. S., Kohl, M., Sauer, T., Hartwig, S., Geisler, S., Lehr, S., & Gemoll, T. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06418-0 · Cited by 2
“…levels, including the genome, epigenome, transcriptome, proteome, and therapy response, which profoundly influences tumour progres - sion, metastasis, and treatment resistance (Lin et al. 2017; McGranahan and Swanton 2017; Molinari et al. 2018; Rayn-aud et al. 2018; Kapoor-Narula and Lenka 2022).”
Krishnakumar, B., Paul, B. C., Prince, S. E., & Baskaran, U. L. (2026) · Personalized Medicine · doi:10.1080/17410541.2026.2634747 · Cited by 1
Clinical applications and future perspectives of circulating tumor cells in solid tumors
Hajizadeh, A., Momeni, F., Eslami, N. M., Rajeh, S. M., Parsian, A., Birgani, R. G., Kananpour, N., Pourzare, P., Aghili, A., samarjan, R. S., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-04799-3 · Cited by 1
Rafeeu, R., Symonds, E. L., Michael, Z. M., Cornthwaite, K. J., Pedersen, S. K., Smith, R. J., Young, G. P., & Winter, J. M. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06512-x · Cited by 1
“However, the high genetic heterogeneity of CRC is a barrier in the widespread clinical application of mutation-based ctDNA assays (Molinari et al. 2018).”
Circulating Tumor DNA in Colorectal Cancer—From Concept to Clinic
Loft, M., Jalali, A., Gibbs, P., Tie, J., & Western Health, F. (2019) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2019.15.1.33 · Cited by 1
Mutational Analysis in Urinary Cell-Free DNA: KRAS in Colorectal Cancer
Molinari, C., & Chiadini, E. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1354-2_3 · Cited by 1
Self-citationTaghizadeh, H., Maj‐Hes, A., Prager, G. W., Müllauer, L., & Mader, R. M. (2022) · Cancers · doi:10.3390/cancers14081936 · Cited by 1
Genetic Analysis of Biopsy Tissues from Colorectal Tumors in Patients with Ulcerative Colitis
Yamamoto, N., Urabe, Y., Nakahara, H., Nakamura, T., Shimizu, D., Konishi, H., Ishibashi, K., Ariyoshi, M., Miyamoto, R., Mizuno, J., et al. (2024) · Cancers · doi:10.3390/cancers16193271 · Cited by 1
“However, as highlighted in previous reports, tumor heterogeneity and the possibility of sampling errors in tumor biopsies remain significant challenges [27,45,46].”
BackgroundAntibody therapy of cancer: Novel therapeutic strategies for prevention and treatment of metastases
Gruijs, M. (2023) · doi:10.5463/thesis.272 · Cited by 1
Current advances in colorectal cancer treatment
Goede, E. K.-D. (2020) · doi:10.3990/1.9789036549899
Geringe Invasivität – hohe Sensitivität: Liquid-Biopsy-Diagnostik bei zielgerichteten Therapien
Holdenrieder, S., & Baraniskin, A. (2021) · Trillium Diagnostik · doi:10.47184/td.2021.02.02
Marbun, V. M. G., Lalisang, T. J. M., & Erlina, L. (2021) · Research Square · doi:10.21203/rs.3.rs-900277/v1
“(1) missense, (2) nonsense; (3) frameshift; (4) silent; (5) splice-site.”
BackgroundNemati, R., Valizadeh, M., Mohammadi, M., & Kamali, A. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101375
Gastrointestinal Cancers and Personalized Medicine
Mini, E., & Nobili, S. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-3807-5
Stellenwert der Liquid Biopsy im Rahmen der Therapie des kolorektalen Karzinoms
Baraniskin, A. (2022) · Gastro-News · doi:10.1007/s15036-022-2530-2
“Allerdings ist die Interpretation der Ergebnisse hier durch intra- und interläsionale Heterogenität des Karzinoms eingeschränkt [6, 7, 8].”
BackgroundAtuação da equipe multiprofissional no cuidado ao paciente oncológico: um relato de experiência
CURSOS, L. C. E. &., Teixeira, J. S. D. S., Farias, I. C., Alves, S. V., Queiroz, A. C. M., Migueis, D. G., dos Santos, J. M., Castro, M. C. P., & Evangelista, M. R. (2022) · Literacia Cientifica Editora & Cursos eBooks · doi:10.53524/lit.edt.978-65-84528-12-3/23
Telessaúde e Atenção Primária à Saúde na pandemia: uma revisão narrativa
CURSOS, L. C. E. &., Cavalcante, A. R., Fonseca, J. R. D. S., Freires, M. G. B., Rocha, F. D. C. S., Gomes, M. B. V., Martins, T. J. B., Brito, V. R. R., & Mendes‐Sousa, A. F. (2022) · Literacia Cientifica Editora & Cursos eBooks · doi:10.53524/lit.edt.978-65-84528-12-3/26
CURSOS, L. C. E. &., Costa, B. H. S., Souza, M. C. D. A., de Medeiros, A. A., da Silva, F. A., Pereira, D. M., Coêlho, L. P. I., Ferreira, R. N., de Goes, A. P., Rocha, D. A. L., et al. (2022) · Literacia Cientifica Editora & Cursos eBooks · doi:10.53524/lit.edt.978-65-84528-12-3/17
Qualidade de vida das mulheres acometidas por endometriose e possíveis intervenções em saúde
CURSOS, L. C. E. &., Pedro, I. S. D. S., Lima, A. S. S., Fernandes, L. N. D. S., Lima, A. K. D. L., dos Santos, C. F. J., dos Santos, G. D., & Silva, M. F. T. S. (2022) · Literacia Cientifica Editora & Cursos eBooks · doi:10.53524/lit.edt.978-65-84528-12-3/21
Metadata
- Authors
- Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P.
- Affiliations
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
- Corresponding author
- Ulivi, Paola
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-11-23
- Volume
- 19
- Issue
- 12
- Pages
- 3733
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6321493
- OpenAlex
- W2901481287
- Cited by
- 262
- References
- 116
- Citations by year
- 2026: 21 · 2025: 24 · 2024: 30 · 2023: 25 · 2022: 84 · 2021: 49 · 2020: 20 · 2019: 9
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- colorectal cancer, tumor heterogeneity, spatial heterogeneity, interpatient variability, metastatic colorectal cancer, anti-EGFR monoclonal antibody, liquid biopsy, minimal residual disease, treatment resistance, personalized medicine, molecular characterization
- MeSH terms
- Liquid Biopsy, Biological Variation, Individual, Humans, Neoplasm Metastasis, Neoplasm Staging, Biomarkers, Tumor, Colorectal Neoplasms, Genetic Heterogeneity, Molecular Diagnostic Techniques, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.